Skip to main content
Submit a Manuscript
Research & Insight
Pathways Beyond Oncology
Comparative Effectiveness Research
Health Economics and Outcomes Research
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Diffuse Large B-Cell Lymphoma
Head and Neck Cancer
Mantle Cell Lymphoma
Non-Small Cell Lung Cancer
Mantle Cell Lymphoma Excellence Forum
Prostate Cancer Excellence Forum
Oncology Clinical Pathways Congress
ASCO Gastrointestinal Cancers Symposium
ASCO Genitourinary Cancers Symposium
SGO Annual Meeting on Women's Cancer
NCCN Annual Conference
Insights from the NCCN Annual Conference
Treatment Patterns After EGFR-TKI and Platinum-Based Chemotherapy Discontinuation in Metastatic NSCLC
April 16, 2021
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Technological Barriers to Telehealth Use for Patients With Cancer
April 08, 2021
Significant disparities in technological knowledge and access to telehealth exist among cancer patients and are largely associated with demographic characteristics.
Biomarker Testing-Guided Treatment Improves Outcomes in Advanced or Metastatic NSCLC
April 07, 2021
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Real-World Use of Pembrolizumab Plus Chemotherapy for NSCLC
April 06, 2021
Patients with NSCLC who receive pembrolizumab with chemotherapy are more likely to remain on therapy past 90 days than those who received chemotherapy alone.
Stay in the know.
Journal of Clinical Pathways Newsletter
Back to Top